Retatrutide Evidence Guide
Retatrutide now has the strongest reported weight-loss signal in the library: Lilly's Phase 3 TRIUMPH-1 topline data showed -28.3% at 80 weeks and up to -30.3% in a 104-week extension subgroup. It is still investigational and unpublished in full, so tirzepatide remains the approved default; retatrutide is the leading next-generation candidate to watch.
Our Take
Retatrutide now has the strongest reported weight-loss signal in the library: Lilly's Phase 3 TRIUMPH-1 topline data showed -28.3% at 80 weeks and up to -30.3% in a 104-week extension subgroup. It is still investigational and unpublished in full, so tirzepatide remains the approved default; retatrutide is the leading next-generation candidate to watch.
- Best for
- Weight loss research, obesity pharmacology, metabolic dysfunction-associated steatotic liver disease
- Evidence grade
- Level B
- Confidence
- Moderate
- Starting point
- Clinical-trial only; TRIUMPH-1 used weekly 4mg, 9mg, and 12mg target doses after stepwise escalation
Benefits and Evidence
- Body Weight Reduction: Level B, includes human evidence - Phase 2 trials demonstrated up to 24.2% body weight reduction at 48 weeks. Lilly's May 2026 TRIUMPH-1 Phase 3 topline data reported -28.3% at 80 weeks with 12mg retatrutide and 45.3% of participants achieving at least 30% weight loss.
- Glycemic Control: Level B, includes human evidence - Significant reductions in HbA1c observed in participants with type 2 diabetes, with improvements correlating to dose and duration of treatment.
- Hepatic Fat Reduction: Level B, includes human evidence - Substantial reduction in liver fat content observed via imaging, attributed to the glucagon receptor agonist component driving hepatic lipid oxidation.
- Gastrointestinal Side Effects: Level B, includes human evidence - Nausea, diarrhea, and vomiting were the most common adverse events, generally mild to moderate and decreasing over time with dose titration.
Side Effects and Warnings
- Nausea
- Diarrhea
- Vomiting
- Decreased appetite
- Constipation
- Injection site reactions
- Not yet approved for clinical use - investigational only
- Risk of gastrointestinal adverse events, especially during dose escalation
Research Dosage References
- <strong>Subcutaneous injection</strong> - 4 mg escalating to 12 mg - Once weekly - Dose titration over several weeks recommended to minimize gastrointestinal side effects. Highest efficacy observed at 12 mg weekly.
- <strong>Subcutaneous injection</strong> - 0.5 mg starting dose - Once weekly - Phase 2 trial starting dose, escalated every 4 weeks to target maintenance dose.
Mechanism of Action
Retatrutide functions as a triple incretin receptor agonist, simultaneously engaging three key metabolic hormone receptors: GLP-1, GIP, and glucagon. This tri-agonist approach represents a significant advancement beyond single and dual agonist therapies. At the GLP-1 receptor, retatrutide enhances glucose-dependent insulin secretion, suppresses glucagon release during hyperglycemia, and slows gastric emptying. These effects reduce postprandial glucose excursions and promote satiety through both peripheral and central mechanisms. GIP receptor activation works synergistically with GLP-1 signaling to potentiate insulin secretion and improve beta-cell function. GIP agonism also appears to enhance the tolerability of the compound by counteracting some of the nausea associated with GLP-1 receptor activation alone. The glucagon receptor agonist component differentiates retatrutide from dual agonists. Glucagon activation increases hepatic energy expenditure, promotes lipolysis, and enhances thermogenesis. This drives additional caloric expenditure and preferentially targets hepatic and visceral fat stores, contributing to the superior weight loss observed in clinical trials.
Legal Status
Investigational - not approved for clinical use. Positive Phase 3 TRIUMPH-1 topline results were announced in May 2026, but retatrutide remains available only through clinical trials.
Primary Sources
- Retatrutide once weekly for treatment of obesity: a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet, 2023.
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease. New England Journal of Medicine, 2024.
- Efficacy and safety of retatrutide in type 2 diabetes: a phase 2 trial. Diabetes Care, 2023.